NewCures Projects
MYC Inhibitors for Cancer Therapy
Sarki Abdulkadir, MD, PhD
Department of Urology
Feinberg School of Medicine
Gary Schiltz, PhD
Center for Molecular Innovation and Drug Discovery
A series of substituted pyrazole small molecular compounds that disrupt MYC/MAX binding to DNA | CANCER
OAT Inhibitor for Hepatocellular Carcinoma
Richard Silverman, PhD
Department of Chemistry
Weinberg College of Arts and Sciences
A potent inactivator of ornithine aminotransferase (OAT) that regulates mitotic cell division in rapidly growing cells | CANCER
Synthetic Lipoprotein Nanoparticle for Lymphoma
C. Shad Thaxton, MD, PhD
Department of Urology
Feinberg School of Medicine
A biomimetic high density lipoprotein that modulates the cellular regulation of cholesterol in B-cell specific non-Hodgkin lymphoma | CANCER
NKG2D Superagonist to Activate Antigen Specific CD8 T Cell Responses
Jennifer Wu, PhD
Department of Urology
Feinberg School of Medicine
Novel first-in-class biological reagent and method to empower the activity of antigen-specific CD8 T cells in situ for a broad indication of cancer immunotherapy and controlling viral infection | CANCER & OTHER
A BACTERIAL CELL WALL COMPONENT INDUCES ANALGESIA
Praveen Thumbikat, PhD
Department of Urology
Feinberg School of Medicine
Use of lipotechoicacid (LTA) as an immune modulator with anti-nociceptive properties for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) | OTHER
Peptide Therapy for Hepatorenal Syndrome
Nathan Gianneschi, PhD
Department of Chemistry
Weinberg College of Arts and Sciences
Payload armed lipid metabolites (PALM) platform technology for albumin-mediated vasoconstrictive therapy | OTHER
Positive Allosteric Modulators of the Human Serotonin Receptor 2c
Herbert Meltzer, MD
Department of Psychiatry and Behavioral Sciences
Feinberg School of Medicine
Karl Scheidt, PhD
Department of Chemistry
Weinberg College of Arts and Sciences
Small molecule drug platform based on the natural products alstonine and serpentine | CNS